RxDoctor Payments DataLook up a doctor →

Justin Field, MD

Internal Medicine · Indianapolis, INNPI 1578946117

Payments from drug & device makers

$49,139in general payments, 2019–2025

Across 422 payments — averaging $116.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$26K
  • Abbott$12K
  • Biotronik Inc.$4K
  • Biosense Webster, Inc.$1K
  • Novartis$647
  • Boston Scientific$629
  • plus $5K from 35 others

What the payments were for

  • Grants$27,44656%
  • Travel & lodging$7,40215%
  • Food & beverage$13,31327%
  • Education$9772%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,139 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$221,252
Medicare patients
575
Services billed
2,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$390,758
Repatha SureclickEvolocumab123$103,282
JardianceEmpagliflozin89$102,935
XareltoRivaroxaban58$68,682
EntrestoSacubitril/Valsartan38$33,917
BrilintaTicagrelor11$12,458
FarxigaDapagliflozin Propanediol14$9,019
Nebivolol Hcl92$5,175
Rosuvastatin Calcium347$4,739
Ezetimibe65$3,851
EdarbiAzilsartan Medoxomil13$3,593
Metoprolol Succinate277$3,408
Valsartan96$2,677
Atorvastatin Calcium253$2,228
Ranolazine ErRanolazine11$2,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$528$390,758324 claims
Boehringer IngelheimJardiance$509$102,93589 claims
Johnson & JohnsonXarelto$185$68,68258 claims
NovartisEntresto$647$33,91738 claims
AstraZenecaBrilinta, Farxiga$166$21,47725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →